Shift Labs and Professor Beth Kolko receive funding to improve maternal and child health

Friday, May 25, 2018

Shift Labs, the medical technology company founded by Human Centered Design & Engineering Professor Beth Kolko, has received funding from Saving Lives at Birth: A Grand Challenge for Development to support the development of their DripAssist device to improve maternal and child health.

DripAssist is a lightweight, battery-operated infusion rate monitor that provides precise flow rate and volume monitoring for IV medication management. It is currently being used throughout the US for outpatient infusion, and it is used in military field hospitals and developing world hospitals.

This funding will allow Professor Kolko and her team at Shift Labs to undergo a rigorous clinical evaluation of their DripAssist infusion rate monitoring device to improve the administration of medications during labor, with the goal of ultimately reducing maternal and newborn deaths in developing nations. Shift Labs will conduct the clinical study in partnership with Kenyatta National Hospital in Nairobi, under the direction of Dr. John Kinuthia, OB/GYN, and will research how nurses use DripAssist for oxytocin and magnesium sulfate administration during and immediately after labor, when a majority of maternal and newborn deaths occur.

Saving Lives at Birth: A Grand Challenge for Development is an international partnership between U.S. Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada (funded by the Government of Canada), the U.K's Department for International Development (DFID) and the Korea International Cooperation Agency (KOICA). The partnership supports groundbreaking prevention and treatment approaches for pregnant women and newborns in poor, hard-to-reach communities around the time of delivery.

Professor Kolko describes DripAssist in this video for Saving Lives at Birth, here:

 

Read the press release about the award on the Shift Labs website, here.